This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tzanela, M. Articles by Shaffer Tannenbaum, G. Search for Related Content PubMed PubMed Citation Articles by Tzanela, M. Articles by Shaffer Tannenbaum, G.

Recombinant Human Growth Hormone-Binding Protein Fails to Enhance the in Vivo Bioactivity of Human Growth Hormone in Normal Rats¹

Departments of Pediatrics, Neurology and Neurosurgery, McGill University; and the Neuropeptide Physiology Laboratory, McGill University-Montreal Children’s Hospital Research Institute, Montreal, Québec H3H 1P3, Canada

Address all correspondence and requests for reprints to: Dr. Gloria S. Tannenbaum, Neuropeptide Physiology Laboratory, McGill University-Montreal Children’s Hospital Research Institute, 2300 Tupper Street, Montreal, Québec H3H 1P3, Canada. E-mail: mcta{at}musica.mcgill.ca

GH circulates in the plasma partially bound with a GH-binding protein (GHBP), but the physiological significance of the GHBP and how it affects GH bioactivity in vivo is still unknown. In the present study, we took advantage of the known biological action of exogenous human (h) GH to inhibit endogenous rat (r) pulsatile GH release and examined the effect of combining hGH with recombinant hGHBP on this response in normal rats. Spontaneous 7-h plasma rGH and hGH profiles were obtained from four groups of free-moving adult male rats sc administered either: 1) 200 µg hGH alone; 2) a mixture of 200 µg hGH and 200 µg hGHBP preincubated for 30 min before injection; 3) 200 µg hGHBP alone; or 4) Tris buffer (vehicle) alone. Rats administered the vehicle or hGHBP separately exhibited the typical pulsatile pattern of rGH secretion. Injection of hGH alone resulted in a marked (P < 0.01) suppression of spontaneous rGH pulses for approximately 3.5 h after the injection compared with vehicle-injected controls; during the subsequent 3.5- to 7-h period, recovery of spontaneous rGH peaks was evident. Plasma levels of hGH in these animals reached a peak within 1 h after hGH injection and declined to near undetectable levels by the end of the sampling period. In contrast, the disappearance rate of hGH was markedly slower in rats administered the hGH + hGHBP complex; plasma hGH concentrations at 7 h after injection were 14-fold higher than those in animals administered hGH alone, and hGH was still readily detectable up to 24 h after injection. However, despite the markedly higher levels of hGH persisting throughout the sampling period in complex-injected rats, both the time course of hGH-induced inhibition of rGH and the recovery of spontaneous rGH pulses were similar to those of animals administered hGH alone. Moreover, there were no significant modifications of plasma insulin-like growth factor-1 levels for up to 24 h after injection of the hGH + hGHBP complex. Computer simulations revealed that most of the total hGH observed during the 3.5- to 7-h period was circulating in the bound form. These results demonstrate that, despite hGHBP’s ability to markedly prolong the bioavailability of hGH, precomplexing hGH with hGHBP failed to enhance hGH’s in vivo bioactivity in the inhibition of endogenous pulsatile rGH release. Our findings do not provide support for the concept that the GHBP enhances the bioactivity of GH in vivo, at least over the time course examined here.

This article has been cited by other articles:

				S. Fisker, K. Kristensen, A. M. Rosenfalck, S. B. Pedersen, L. Ebdrup, B. Richelsen, J. Hilsted, J. S. Christiansen, and J. O. L. Jørgensen Gene Expression of a Truncated and the Full-Length Growth Hormone (GH) Receptor in Subcutaneous Fat and Skeletal Muscle in GH-Deficient Adults: Impact of GH Treatment J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 792 - 796. [Abstract] [Full Text]

				H. K. Choi and D. J. Waxman Plasma Growth Hormone Pulse Activation of Hepatic JAK-STAT5 Signaling: Developmental Regulation and Role in Male-Specific Liver Gene Expression Endocrinology, September 1, 2000; 141(9): 3245 - 3255. [Abstract] [Full Text] [PDF]

				A. Edens and F. Talamantes Alternative Processing of Growth Hormone Receptor Transcripts Endocr. Rev., October 1, 1998; 19(5): 559 - 582. [Abstract] [Full Text]